1. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(5):571-8.
2. Suh KJ, Kim KH, Kim R, Byun JM, Kim M, Park JH, et al. Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. The Korean journal of internal medicine. 2019;34(4):894-901.
3. Zhang Y, Fan Y, Ying Z, Song Y, Zhu J, Yang Z, et al. Can the SUV(max-liver)-based interpretation improve prognostic accuracy of interim and posttreatment (18)F-FDG PET/CT in patients with diffuse large B-cell lymphoma? Leukemia & lymphoma. 2018;59(3):660-9.
4. Winter A, Rybicki L, Shah SN, Jagadeesh D, Gerds AT, Hamilton BK, et al. Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leukemia & lymphoma. 2018;59(5):1195-201.
5. Novelli S, Briones J, Flotats A, Sierra J. PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2015;24(2):325-30.
6. Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. American journal of hematology. 2009;84(6):338-43.
7. Hofman MS, Hicks RJ. Using positron emission tomography to assess tumor proliferation in non-Hodgkin lymphoma. Leukemia & lymphoma. 2010;51(2):183-5.
8. Storto G, Di Giorgio E, De Renzo A, Pizzuti LM, Cerciello G, Nardelli A, et al. Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma. British journal of haematology. 2010;151(2):195-7.
9. Meyer HJ, Wienke A, Surov A. Correlations Between Imaging Biomarkers and Proliferation Index Ki-67 in Lymphomas: A Systematic Review and Meta-Analysis. Clinical lymphoma, myeloma & leukemia. 2019;19(6):e266-e72.
10. Albano D, Bosio G, Giubbini R, Bertagna F. 18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. Leukemia & lymphoma. 2017;58(10):2328-34.
11. Angelopoulou MK, Mosa E, Pangalis GA, Rondogianni P, Chatziioannou S, Prassopoulos V, et al. The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials. Anticancer research. 2017;37(10):5727-36.
12. Isik EG, Kuyumcu S, Kebudi R, Sanli Y, Karakas Z, Cakir FB, et al. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of (18)FDG-PET/CT according to ΔSUV(max), Deauville 5-point scale and IHP criteria. Annals of nuclear medicine. 2017;31(9):660-8.
13. Wang K, Zhao X, Chen Q, Fan D, Qiao Z, Lin S, et al. A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images. Medicine. 2017;96(32):e7756.
14. Hoffmann M, Kletter K, Diemling M, Becherer A, Pfeffel F, Petkov V, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Annals of oncology : official journal of the European Society for Medical Oncology. 1999;10(10):1185-9.
15. Hoffmann M, Kletter K, Becherer A, Jäger U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology. 2003;64(4):336-40.
16. Ambrosini V, Rubello D, Castellucci P, Nanni C, Farsad M, Zinzani P, et al. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nuclear medicine review Central & Eastern Europe. 2006;9(1):37-40.
17. Radan L, Fischer D, Bar-Shalom R, Dann EJ, Epelbaum R, Haim N, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. European journal of nuclear medicine and molecular imaging. 2008;35(8):1424-30.
18. Fu L, Li H, Wang H, Xu B, Fan Y, Tian J. SUVmax/THKmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma. PloS one. 2012;7(12):e50914.
19. Perry C, Herishanu Y, Metzer U, Bairey O, Ruchlemer R, Trejo L, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. European journal of haematology. 2007;79(3):205-9.
20. Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematological oncology. 2010;28(2):57-61.
21. Sharma P, Suman SK, Singh H, Sharma A, Bal C, Malhotra A, et al. Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment. Leukemia & lymphoma. 2013;54(5):951-8.
22. Hwang JP, Lim I, Byun BH, Kim BI, Choi CW, Lim SM. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma. Nuclear medicine communications. 2016;37(12):1267-72.
23. Li XF, Fu Q, Dong YW, Liu JJ, Song XY, Dai D, et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma. World journal of gastroenterology. 2016;22(34):7787-96.
24. Bennett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation. Annals of oncology : official journal of the European Society for Medical Oncology. 1991;2 Suppl 2:83-92.
25. Skarin AT, Canellos GP. Chemotherapy of advanced non-Hodgkin's lymphoma. Clinics in haematology. 1979;8(3):667-84.
26. Brown DC, Heryet A, Gatter KC, Mason DY. The prognostic significance of immunophenotype in high-grade non-Hodgkin's lymphoma. Histopathology. 1989;14(6):621-7.
27. Watanabe R, Tomita N, Takeuchi K, Sakata S, Tateishi U, Tanaka M, et al. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leukemia & lymphoma. 2010;51(2):279-83.
28. Gerdes J, Pileri S, Bartels H, Stein H. [Proliferation marker Ki-67: correlation with histological diagnosis, neoplasm grading and clinical course]. Verhandlungen der Deutschen Gesellschaft fur Pathologie. 1986;70:152-8.
29. Ding CY, Liu HY, Guo Z, Li TN. [Value of Pretherapeutic (18)F-FDG PET/CT in the Diagnosis, Staging and Prognosis Evaluation of Adult Burkitt's Lymphoma]. Zhongguo shi yan xue ye xue za zhi. 2017;25(2):438-43.
30. Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, et al. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. European journal of haematology. 2015;94(6):532-9.
31. Liang JH, Sun J, Wang L, Fan L, Chen YY, Qu XY, et al. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma. Oncotarget. 2016;7(14):19072-80.
32. Huang H, Xiao F, Han X, Zhong L, Zhong H, Xu L, et al. Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma. Nuclear medicine communications. 2016;37(7):689-98.